Opioid-induced Constipation Epidemiology Forecast 2025-2034

Opioid-induced constipation (OIC) affects a significant portion of patients receiving opioids, with estimates ranging from 40% to 60% in those without cancer. To prevent the condition, it is recommended that laxatives be started at the same time as opioid therapy.

Opioid-induced Constipation Epidemiology Forecast Report Coverage

The “Opioid-induced Constipation Epidemiology Forecast Report 2025-2034” offers comprehensive information on the prevalence and demographics of opioid-induced constipation. It projects the future incidence and prevalence rates of opioid-induced constipation across various populations. The study covers age and type as major determinants of the opioid-induced constipation-affected population. The report highlights patterns in the prevalence of opioid-induced constipation over time and projects future trends based on multiple variables.

The report provides a comprehensive overview of the disease, as well as historical and projected data on the epidemiology of opioid-induced constipation in the 8 major markets.

Regions Covered

• The United States
• Germany
• France
• Italy
• Spain
• The United Kingdom
• Japan
• India

Opioid-induced Constipation Understanding: Disease Overview

Opioid-induced constipation is a side effect of opioid use. Opioids are commonly prescribed for pain relief. They bind to receptors in the gastrointestinal (GI) tract, reducing motility and causing a slowdown in bowel movements. This results in constipation, which can be severe and persistent in many patients. Opioid-induced constipation can affect anyone using opioids long-term, including patients with chronic pain or who are undergoing cancer treatment. Symptoms of OIC include infrequent bowel movements, straining, hard stools, bloating, and abdominal discomfort.

Opioid-induced Constipation Epidemiology Perspective

The opioid-induced constipation epidemiology section offers information on the patient pool from history to the present as well as the projected trend for each of the 8 major markets. The publisher provides both current and predicted trends for opioid-induced constipation by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for opioid-induced constipation and their trends. The data is broken down into specific categories, such as the total diagnosed cases across different age groups and patient pools.

• About 40% to 60% of patients without cancer who are taking opioids are estimated to be affected by opioid-induced constipation.
• The prevalence of opioid-induced constipation ranges from 8.9% to 81.0% worldwide, as per international studies.
• According to a study published in the International Journal of Clinical Oncology (2021), which included 50 Japanese patients with gastrointestinal cancer (colon 50%, stomach 28%, esophageal 22%), the incidence of opioid-induced constipation ranged from 46.0% to 62.0%, depending on the diagnostic criteria.
• Various studies suggest that 40% to 80% of individuals undergoing chronic opioid therapy develop opioid-induced constipation.

Country-wise Opioid-induced Constipation Epidemiology

The opioid-induced constipation epidemiology data and findings for the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, and India are also provided in the epidemiology section.

The epidemiology of opioid-induced constipation varies significantly between countries due to differences in differences in opioid prescribing practices, healthcare systems, cultural attitudes toward pain management, the prevalence of chronic pain conditions, and the availability of preventive treatments, among others. In a United States survey published in the American Journal of Gastroenterology (2023), Rome IV opioid-induced constipation (OIC) was found in 1.7% of individuals, while Rome IV opioid-exacerbated constipation (OEC) was less common at 0.4%.

Key Questions Answered

• What are the key findings of opioid-induced constipation epidemiology in the 8 major markets?
• What will be the total number of patients with opioid-induced constipation across the 8 major markets during the forecast period?
• What was the country-wise prevalence of opioid-induced constipation in the 8 major markets in the historical period?
• Which country will have the highest number of opioid-induced constipation patients during the forecast period of 2025-2034?
• Which key factors would influence the shift in the patient population of opioid-induced constipation during the forecast period of 2025-2034?
• What are the currently available treatments for opioid-induced constipation?
• What are the disease risks, signs, symptoms, and unmet needs of opioid-induced constipation?

This product will be delivered within 3-5 business days.